EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of plasma p‐tau217/Aβ42, p‐tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease

Katheryn A Q Cousins, Magdalena Korecka, Yang Wan, Amberley Vulaj, Christopher Brown, Thomas F Tropea, Edward B Lee, Duygu Tosun, Susan M Landau, Ozioma C Okonkwo, Monica Rivera Mindt, Michael W Weiner und 4 weitere

Alzheimer's & Dementia · 2025-08 · 21 (8)

DOI: 10.1002/alz.70469 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Alzheimer's & Dementia, online erschienen am 13.08.2025. Verfasst von Katheryn A Q Cousins und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Peptide Fragments, tau Proteins. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION In clinically and racially diverse training and test sets, we evaluated and validated Alzheimer's disease (AD) plasma biomarkers: phosphorylated tau‐217 (p‐tau217), amyloid beta 1‐42/1‐40 (Aβ42/Aβ40), and p‐tau217/Aβ42. METHODS Inclusion criteria were available plasma, race (people who self‐identified as Black/African American [pBlack] or White [pWhite]), cognitive status (normal, mild cognitive impairment [MCI], dementia), and 18 F‐florbetaben or 18 F‐florbetapir positron emission tomography (PET) data. In the training set ( n = 289; 28% pBlack), we used receiver‐operating characteristic (ROC) analysis to calculate two cut points (0.95 sensitivity and specificity) to detect amyloid PET positivity. Cut points were validated in an independent test set ( n = 846; 12% pBlack). RESULTS In the test set, plasma p‐tau217/Aβ42 had the highest accuracy (pBlack: 0.88, pWhite: 0.91) and lowest proportion of intermediate classifications (≤0.16), with no classification difference by race (odds ratio [OR] = 1.45, 95% confidence interval [CI] = 0.66–2.95, p = 0.33). False negatives were more likely to be cognitively normal (vs mild cognitive impairment [MCI]; OR = 7.79, 95% CI = 2.33–40.81, p = 5.1e‐05) than correct classifications. DISCUSSION Plasma p‐tau217/Aβ42 had high accuracy to detect AD, with comparable performance across race. Highlights We tested plasma phosphorylated tau‐217 (p‐tau217)/amyloid beta (Aβ) 42 , p‐tau217, and Aβ42/Aβ40 in diverse training and test sets. In models, race × amyloid PET interactions were not significant. Plasma p‐tau217/Aβ42 had the highest accuracy in people who self‐identified as Black/African American (pBlack; 0.88) and people who self‐identified as White (pWhite; 0.91). Plasma p‐tau217/Aβ42 had the lowest proportion of intermediate cases (range = 0.09–0.16). False negatives were more likely to have normal cognition, female sex, and high body mass index.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesPeptide Fragmentstau ProteinsAgedAged, 80 and overFemaleHumansMaleAniline CompoundsBiomarkersBlack or African AmericanCognitive DysfunctionPhosphorylationPositron-Emission TomographyWhite

Stichwörter der Autor:innen

Alzheimer's diseaseAβ42/Aβ40cognitiondifferential diagnosisplasma biomarkersp‐tau217p‐tau217/Aβ42racetest–retest

Substanzen

Amyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)Aniline CompoundsBiomarkersMAPT protein, humanPeptide Fragmentstau Proteins

Autor:innen und Institutionen

  • Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA.
  • Neuroscience Department, University of California, Berkeley, California, USA.
  • Department of Medicine and the Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, USA.
  • Department of Psychology, Fordham University, New York, New York, USA.

Förderung

  • NIA NIH HHS
  • National Institute on Aging

Zitieren

APA

Cousins, K. A. Q., Korecka, M., Wan, Y., Vulaj, A., Brown, C., Tropea, T. F., Lee, E. B., Tosun, D., Landau, S. M., Okonkwo, O. C., Mindt, M. R., Weiner, M. W., Irwin, D. J., Wolk, D. A., Shaw, L. M., & Alzheimer's Disease Neuroimaging Initiative (2025). Comparison of plasma p‐tau217/Aβ42, p‐tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease. Alzheimer's & Dementia, 21(8). https://doi.org/10.1002/alz.70469

Vancouver

Cousins KAQ, Korecka M, Wan Y, Vulaj A, Brown C, Tropea TF, et al. Comparison of plasma p‐tau217/Aβ42, p‐tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease. Alzheimer's & Dementia. 2025;21(8). doi:10.1002/alz.70469

BibTeX
@article{Cousins2025,
  author = {Cousins, Katheryn A Q and Korecka, Magdalena and Wan, Yang and Vulaj, Amberley and Brown, Christopher and Tropea, Thomas F and Lee, Edward B and Tosun, Duygu and Landau, Susan M and Okonkwo, Ozioma C and Mindt, Monica Rivera and Weiner, Michael W and Irwin, David J and Wolk, David A and Shaw, Leslie M and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
  title = {Comparison of plasma p‐tau217/Aβ42, p‐tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {8},
  doi = {10.1002/alz.70469}
}
Kostenlos starten →